{"id":82597,"date":"2025-08-19T11:19:10","date_gmt":"2025-08-19T11:19:10","guid":{"rendered":"https:\/\/www.merckconnect.ca\/en\/?post_type=mhh-sticky-footer&#038;p=82597"},"modified":"2026-06-10T12:01:33","modified_gmt":"2026-06-10T12:01:33","slug":"delstrigo-pifeltro","status":"publish","type":"mhh-sticky-footer","link":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/","title":{"rendered":"DELSTRIGO-PIFELTRO"},"content":{"rendered":"<div class=\"mhh-sticky-footer-panel mhh-sticky-footer-panel--7e649791516fc7f592b874f10e846537\">\n    <button class=\"mhh-sticky-footer-panel__expand-button\" \n            data-event-name=\"accordion_click\" \n            data-design-module=\"indication\"\n            data-design-category=\"accordion\"\n            data-design-label=\"expand\">\n                    <svg\n            xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n            fill=\"currentColor\"\n            viewBox=\"0 0 16 16\"\n            >\n            <path\n            d=\"M8 4a.5.5 0 0 1 .5.5v3h3a.5.5 0 0 1 0 1h-3v3a.5.5 0 0 1-1 0v-3h-3a.5.5 0 0 1 0-1h3v-3A.5.5 0 0 1 8 4z\"\/>\n            <\/svg>\n                <span>EXPAND<\/span>\n        <\/button>\n    <div class=\"mhh-sticky-footer-inner\">\n    \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--5e861fc389f47d387c6a4327b30cd100\"><a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/DELSTRIGO-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">DELSTRIGO\u00ae Product Monograph<\/a><\/p>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-object-object-font-size mhh-mcn-v1-paragraph--right  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--249dac455f3eb2d02d69b620fb784719\"><a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/PIFELTRO-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">PIFELTRO\u00ae Product Monograph<\/a><\/p>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color wp-elements-adc3c888290645fe556777b930baaeb8 mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--649485da719918910edf9a93dd7533a2\" style=\"background-color:#12b7c1\"><strong>IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n\n    <\/div>\n<\/div>\n\n\n<div class=\"mhh-sticky-footer-expanded-panel mhh-sticky-footer-expanded-panel--f50bf3832e14000c7dbe72662d79e6cc \" dir=\"ltr\">\n    <div class=\"mhh-sticky-footer-expanded-panel__inner\">\n        <div class=\"mhh-sticky-footer-expanded-panel__close-button-wrapper\">\n            <button class=\"mhh-sticky-footer-expanded-panel__close-button\">\n                        <svg\n                xmlns=\"http:\/\/www.w3.org\/2000\/svg\"\n                fill=\"currentColor\"\n                viewBox=\"0 0 16 16\"\n            >\n                <path\n                d=\"M4.646 4.646a.5.5 0 0 1 .708 0L8 7.293l2.646-2.647a.5.5 0 0 1 .708.708L8.707 8l2.647 2.646a.5.5 0 0 1-.708.708L8 8.707l-2.646 2.647a.5.5 0 0 1-.708-.708L7.293 8 4.646 5.354a.5.5 0 0 1 0-.708z\"\/>\n            <\/svg>\n                                    <\/button>\n        <\/div>\n        <div class=\"mhh-sticky-footer-expanded-panel__body\">\n            \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-white-color has-text-color  has-link-color has-object-object-font-size wp-elements-6cc733bc048d868a3703ff870856ad4e mhh-mcn-v1-paragraph--center  mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--32c9553a47f21ce7a55bbfeecd8f597b\" style=\"background-color:#12b7c1\"><strong>IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n\n\n<div class=\"mhh-mcn-columns mhh-mcn-v1-columns--2e709ecefeb9a116ce1c4843447815f7 mhh-mcn-v1-columns mhh-mcn-columns--gutter-m\">\n    <div class=\"mhh-mcn-columns-inner\">\n        \n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--154a9c0f7855f4d15f866c319d8e87bc mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-text-color has-link-color has-object-object-font-size wp-elements-a42552ae2a95e7bf7b91900c1242d907   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--444b58a98debb604c84fa7d19dbd3007\" style=\"color:#c0581a\"><strong>DELSTRIGO<\/strong>\u00ae<strong><sup>&nbsp;<\/sup>IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--ac267016f8f9e59dc8116270e298d0a6\"><strong><span style=\"text-decoration: underline\">Indications and clinical use:<\/span><\/strong><br>DELSTRIGO\u00ae (doravirine\/lamivudine\/tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults and pediatric patients <span class=\"no-text-breaking\">12 years<\/span> of age and older and weighing at least <span class=\"no-text-breaking\">35 kg<\/span> without past or present evidence of viral resistance to doravirine, lamivudine, or tenofovir. The safety and efficacy of DELSTRIGO\u00ae<sup> <\/sup>have not been established in patients younger than <span class=\"no-text-breaking\">12 years<\/span> of age and weighing less than <span class=\"no-text-breaking\">35 kg<\/span>. Limited data on use in patients <span class=\"no-text-breaking\">\u2265 65 years<\/span>.<br><br><strong><u>Contraindications:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--24bddbe4e80c059f65e06bee15a1c676 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use with drugs that are strong CYP3A enzyme inducers, including but not limited to the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent mitotane; and St. John\u2019s wort <em>(Hypericum perforatum)<\/em>    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--32fa6c348019156ba630edb75de9af59\"><strong><u>Most serious warnings and precautions:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--9c39e86c864ea0e1128951265167198f mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Chronic HBV infection<\/strong>: Not approved for treatment of chronic HBV infection, and safety and efficacy not established in coinfected patients. Severe acute exacerbations of HBV have been reported in coinfected HBV\/HIV-1 patients who discontinued lamivudine or tenofovir DF, two of the components of DELSTRIGO\u00ae. Monitor closely with clinical and laboratory follow-up for at least several months after stopping treatment. If appropriate, initiate anti-hepatitis B therapy, especially in patients with advanced liver disease or cirrhosis, since post-treatment exacerbation of hepatitis may lead to hepatic decompensation and liver failure    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Nephrotoxicity: <\/strong>Renal impairment including cases of acute renal failure and Fanconi syndrome has been reported with the use of tenofovir disoproxil fumarate (TDF)    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Breastfeeding: <\/strong>Mothers should not breastfeed if they are receiving DELSTRIGO\u00ae    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9eda731e56ee99f5c7c618ce340c384e\"><strong><u>Other relevant warnings and precautions:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--7b1d8d592734dc8b5b6ae98221554697 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Do not administer with other antiretroviral drugs, with adefovir dipivoxil, or with single-agent doravirine unless doravirine dose adjustment required    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Should not be used in antiretroviral-experienced patients with resistance mutations to doravirine, lamivudine, or tenofovir or with suspected such mutations if no genotype is available    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Bone loss and mineralization defects associated with TDF    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Avoid driving and operating machinery if fatigue, dizziness, and somnolence occur    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Avoid concomitant use with moderate CYP3A inducers, or if coadministration cannot be avoided, <span class=\"no-text-breaking\">1 tablet<\/span> of doravirine <span class=\"no-text-breaking\">100 mg (PIFELTRO\u00ae)<\/span> should be taken approximately <span class=\"no-text-breaking\">12 hours<\/span> after the dose of DELSTRIGO\u00ae    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Increased TDF exposure when used with certain HCV regimens    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Consider measurement of serum lipids and blood glucose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Very rare occurrences of pure red cell aplasia reported with lamivudine use    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Lactic acidosis\/severe hepatomegaly with steatosis, including fatal cases, have been reported    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Immune reconstitution inflammatory syndrome    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Angioedema has been reported in patients taking TDF    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    New onset or worsening renal impairment with TDF    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Physicians are encouraged to report pregnancy cases to the Antiretroviral Pregnancy Registry: <a href=\"http:\/\/www.apregistry.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/www.apregistry.com\/<\/a>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe skin reactions, including toxic epidermal necrolysis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Special care advised in patients <span class=\"no-text-breaking\">\u2265 65 years<\/span> of age due to age-associated changes (e.g., decreases in renal function)    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Not recommended in patients with estimated creatinine clearance <span class=\"no-text-breaking\">&lt;50 mL\/min<\/span>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Not studied in patients with severe hepatic impairment, therefore caution is advised    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Emergence of lamivudine-resistant HBV    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Patients coinfected with HIV-1 and HBV or HCV are at increased risk for severe hepatic adverse events    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color  has-link-color mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--20ab107bd2d470efb98116747ff8b7d6\"><span style=\"text-decoration: underline\"><strong>For more information:<\/strong><\/span><br>Please consult the <a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/DELSTRIGO-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Product Monograph<\/a> for important information relating to contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information, which have not&nbsp; been discussed in this piece. The Product Monograph is also available by calling <span class=\"no-text-breaking\">1-800-567-2594<\/span>.<br><br><strong>Reference:<\/strong> DELSTRIGO\u00ae Product Monograph. Merck Canada Inc. <span class=\"no-text-breaking\">September 23, 2025.<\/span><\/p>\n\n<\/div>\n\n\n<div class=\"mhh-mcn-v1-column mhh-mcn-v1-column--eaf89e92ead6ab3e4bda892771afc29c mhh-mcn-column mhh-mcn-column--12 mhh-mcn-column--m-6 mhh-mcn-column--l-6\">\n    \n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color has-text-color has-link-color has-object-object-font-size wp-elements-32b2df0b7756226a0063b5fa88cc897d   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--7ee7fdd40dbdd159c1c205cd56861d8d\" style=\"color:#12b7c1\"><strong>PIFELTRO<\/strong>\u00ae<strong>&nbsp;IMPORTANT SAFETY INFORMATION<\/strong><\/p>\n\n\n\n<p class=\"has-black-color has-text-color has-link-color has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9e21d103cb6d2690316fcbc9ec9198a2\"><strong><span style=\"text-decoration: underline\">Indications and clinical use:<\/span><\/strong><br>PIFELTRO\u00ae (doravirine) is indicated, in combination with other antiretroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients <span class=\"no-text-breaking\">12 years<\/span> of age and older and weighing at least <span class=\"no-text-breaking\">35 kg<\/span> without past or present evidence of viral resistance to doravirine. The safety and efficacy of PIFELTRO\u00ae in pediatric patients <span class=\"no-text-breaking\">\u226512 years<\/span> of age and weighing at least <span class=\"no-text-breaking\">35 kg<\/span> receiving doravirine 100 mg once daily has been established. Safety and efficacy of PIFELTRO\u00ae have not been established in patients younger than <span class=\"no-text-breaking\">12 years<\/span> of age weighing less than <span class=\"no-text-breaking\">35 kg<\/span>. There are limited data available on the use of doravirine in patients aged <span class=\"no-text-breaking\">65 years<\/span> and over. <br><br><strong><u>Contraindications:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--24b4af44d80087791b92bab3a0d13b27 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Use with drugs that are strong CYP3A enzyme inducers, including but not limited to the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent mitotane; and St. John\u2019s wort (<em>Hypericum perforatum<\/em>)    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--04a6791961211f1baa01c9e907089b9a\"><strong><u>Most serious warning and precaution:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--c3e4efc53bdb303d0cff7cecd89dc4a6 mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    <strong>Breastfeeding<\/strong>: Mothers should not breastfeed if they are receiving PIFELTRO\u00ae    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--9eda731e56ee99f5c7c618ce340c384e\"><strong><u>Other relevant warnings and precautions:<\/u><\/strong><\/p>\n\n\n\n<ul class=\"mhh-mcn-v2-clist mhh-mcn-v2-clist--9682db0c085272e13544d8cf8e07d87a mhh-mcn-list mhh-mcn-v2-clist--unordered mhh-mcn-v2-clist--unordered-dot\" dir=\"ltr\" lang=\"en-US\">\n    \n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Has not been evaluated in patients with previous virologic failure to any other antiretroviral therapy    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Should not be used in antiretroviral-experienced patients with NNRTI resistance mutations which may confer resistance to doravirine or with suspected NNRTI resistance in virologically suppressed patients if no genotype is available    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Avoid driving and operating machinery if fatigue, dizziness, and somnolence occur    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Caution when coadministering with drugs that may reduce doravirine exposure\u00a0    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Consider measurement of serum lipids and blood glucose    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Immune reconstitution inflammatory syndrome    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Physicians are encouraged to report pregnancy cases to the Antiretroviral Pregnancy Registry: <a href=\"http:\/\/www.apregistry.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">http:\/\/www.apregistry.com\/<\/a>    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Severe skin reactions, including toxic epidermal necrolysis    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Not studied in end-stage renal disease or dialysis\u00a0    <\/li>\n\n\n<li class=\"mhh-mcn-list-item mhh-mcn-v2-list-item\">\n    Not studied in patients with severe hepatic impairment    <\/li>\n\n<\/ul>\n\n\n\n<p class=\"has-object-object-font-size has-border-color has-has-red-border-color-border-color  has-link-color mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--29bb9edfb34cefbccba0fb81ad31e77b\"><span style=\"text-decoration: underline\"><strong>For more information:<\/strong><\/span><br>Please consult the <a href=\"https:\/\/www.merck.ca\/en\/wp-content\/uploads\/sites\/20\/2021\/04\/PIFELTRO-PM_E.pdf\" target=\"_blank\" rel=\"noreferrer noopener\">Product Monograph<\/a> for important information relating to contraindications, warnings and precautions, adverse reactions, drug interactions, and dosing information, which have not&nbsp; been discussed in this piece. The Product Monograph is also available by calling <span class=\"no-text-breaking\">1-800-567-2594.<\/span><br><br><br><strong>Reference<\/strong>: PIFELTRO\u00ae Product Monograph. Merck Canada Inc. <span class=\"no-text-breaking\">September 23, 2025.<\/span><br><\/p>\n\n<\/div>\n\n    <\/div>\n\n    <\/div>\n\n\n\n<p dir=\"ltr\" lang=\"en-US\" class=\"has-border-color has-has-red-border-color-border-color   mhh-mcn-v1-paragraph mhh-mcn-v1-paragraph--66efa0af5e606cd6a633107de2769097\">CYP3A=cytochrome P450, family 3, <span class=\"no-text-breaking\">subfamily A;<\/span> HBV=hepatitis B virus; HIV=human immunodeficiency virus; DF=disoproxil fumarate; TDF=tenofovir disoproxil fumarate; HCV=hepatitis C virus; NNRTI=non-nucleoside reverse transcriptase inhibitors<\/p>\n\n        <\/div>\n    <\/div>\n<\/div>\n\n\n\n<div class=\"mhh-sticky-footer-safety-content\">\n    <\/div>\n","protected":false},"template":"","meta":{"_mhh_sticky_footer_settings":{"entityId":0},"_mhh_sticky_footer_posts":"","_mhh_sticky_footer_expanded":false,"_mhh_mcn_text_direction":"","_mhh_mcn_language":"","_mhh_mcn_left_sidebar_settings":{"entityId":0},"_mhh_mcn_sidebar_settings":{"entityId":0},"mhh_mcn_side_navigation_style":{"fontSize":{"l":"","m":"","s":""},"lineHeight":{"l":1.5,"m":1.5,"s":1.5},"itemColor":"","hoverItemColor":"","currentItemColor":"","borderItemColor":"","backgroundItemHoverColor":"","themeColor":""},"_mhh_mcn_child_page_navigation":{"isActive":false,"isSticky":false},"promomats_ca_generated_at":0,"promomats_ca_screen_sizes":["Desktop","Mobile"],"footnotes":""},"mh-depends-on":[],"class_list":["post-82597","mhh-sticky-footer","type-mhh-sticky-footer","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>DELSTRIGO-PIFELTRO | Merck Connect Canada<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DELSTRIGO-PIFELTRO | Merck Connect Canada\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck Connect Canada\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-10T12:01:33+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/\",\"name\":\"DELSTRIGO-PIFELTRO | Merck Connect Canada\",\"isPartOf\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\"},\"datePublished\":\"2025-08-19T11:19:10+00:00\",\"dateModified\":\"2026-06-10T12:01:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.merckconnect.ca\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DELSTRIGO-PIFELTRO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#website\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"name\":\"Merck Connect Canada\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#organization\",\"name\":\"Merck Connect Canada\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"contentUrl\":\"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png\",\"width\":1284,\"height\":331,\"caption\":\"Merck Connect Canada\"},\"image\":{\"@id\":\"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DELSTRIGO-PIFELTRO | Merck Connect Canada","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/","og_locale":"en_US","og_type":"article","og_title":"DELSTRIGO-PIFELTRO | Merck Connect Canada","og_url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/","og_site_name":"Merck Connect Canada","article_modified_time":"2026-06-10T12:01:33+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/","url":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/","name":"DELSTRIGO-PIFELTRO | Merck Connect Canada","isPartOf":{"@id":"https:\/\/www.merckconnect.ca\/en\/#website"},"datePublished":"2025-08-19T11:19:10+00:00","dateModified":"2026-06-10T12:01:33+00:00","breadcrumb":{"@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.merckconnect.ca\/en\/mhh-sticky-footer\/delstrigo-pifeltro\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.merckconnect.ca\/en\/"},{"@type":"ListItem","position":2,"name":"DELSTRIGO-PIFELTRO"}]},{"@type":"WebSite","@id":"https:\/\/www.merckconnect.ca\/en\/#website","url":"https:\/\/www.merckconnect.ca\/en\/","name":"Merck Connect Canada","description":"","publisher":{"@id":"https:\/\/www.merckconnect.ca\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.merckconnect.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.merckconnect.ca\/en\/#organization","name":"Merck Connect Canada","url":"https:\/\/www.merckconnect.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","contentUrl":"https:\/\/www.merckconnect.ca\/en\/wp-content\/uploads\/sites\/4\/2023\/06\/Merck_Connect_Wordmark_Only_RGB.png","width":1284,"height":331,"caption":"Merck Connect Canada"},"image":{"@id":"https:\/\/www.merckconnect.ca\/en\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/82597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer"}],"about":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/types\/mhh-sticky-footer"}],"version-history":[{"count":17,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/82597\/revisions"}],"predecessor-version":[{"id":85222,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mhh-sticky-footer\/82597\/revisions\/85222"}],"wp:attachment":[{"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/media?parent=82597"}],"wp:term":[{"taxonomy":"mh-depends-on","embeddable":true,"href":"https:\/\/www.merckconnect.ca\/en\/wp-json\/wp\/v2\/mh-depends-on?post=82597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}